Brief: Praxis Precision Medicines Announces Positive Results In Patients With Focal Onset Seizures From Vormatrigine
04/08/2025 13:34
Aug 4 (Reuters) - Praxis Precision Medicines Inc PRAX.O: PRAXIS PRECISION MEDICINES ANNOUNCES POSITIVE, BEST-IN-DISEASE TOPLINE RESULTS IN PATIENTS WITH FOCAL ONSET SEIZURES FROM THE RADIANT STUDY OF VORMATRIGINE PRAXIS PRECISION MEDICINES INC - VORMATRIGINE SHOWS 56.3% MEDIAN REDUCTION IN SEIZURE FREQUENCY PRAXIS PRECISION MEDICINES INC - 22% OF PATIENTS ACHIEVE 100% SEIZURE REDUCTION WITH VORMATRIGINE PRAXIS PRECISION MEDICINES INC - 54% OF PATIENTS ACHIEVE 50% RESPONSE IN FIRST WEEK PRAXIS PRECISION MEDICINES INC - VORMATRIGINE DEMONSTRATES FAVORABLE SAFETY PROFILE Source text: ID:nGNX2kBTlJ Further company coverage: PRAX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Praxis Precision Medicines
See all newsUS RESEARCH ROUNDUP-Arxis, Cigna, Vylor
Brief: Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Praxis Precision Medicines, Inc. reports results for the quarter ended June 30 - Earnings Summary
Praxis Precision Q2 net loss widens on higher expenses
Brief: Praxis Precision Q2 EPS USD -2.87